Cargando…
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study
Several authors reported an increased risk of cancer in SSc patients, including breast cancer (BC). Nevertheless, the mechanisms underlying this association have not yet been clarified. SSc and BC share several molecular pathways, which seem to play a common etiopathogenetic role. The previously pub...
Autores principales: | Isca, Chrystel, Spinella, Amelia, Toss, Angela, de Pinto, Marco, Ficarra, Guido, Fabbiani, Luca, Iannone, Anna, Magnani, Luca, Lumetti, Federica, Macripò, Pierluca, Vacchi, Caterina, Gasparini, Elisa, Piana, Simonetta, Cortesi, Laura, Maiorana, Antonino, Salvarani, Carlo, Dominici, Massimo, Giuggioli, Dilia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780893/ https://www.ncbi.nlm.nih.gov/pubmed/36556228 http://dx.doi.org/10.3390/jpm12122007 |
Ejemplares similares
-
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study
por: Toss, Angela, et al.
Publicado: (2021) -
Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers
por: Spinella, Amelia, et al.
Publicado: (2022) -
Infections of scleroderma digital ulcers: A single center cohort retrospective study
por: Giuggioli, Dilia, et al.
Publicado: (2021) -
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
por: Omarini, Claudia, et al.
Publicado: (2020) -
One‐year clinical experience on the use of Nintedanib in systemic sclerosis
por: Magnani, Luca, et al.
Publicado: (2023)